Quick Answer
Kiniksa Pharmaceuticals International, plc reported Cash and Equivalents of $165.60 million for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $165.60M | -9.8% |
| 2024 | $183.58M | +70.1% |
| 2023 | $107.95M | -12.0% |
| 2022 | $122.72M | +0.2% |
| 2021 | $122.47M | +7.4% |
| 2020 | $114.04M | +143.0% |
| 2019 | $46.93M | -34.8% |
| 2018 | $71.98M | +58.0% |
| 2017 | $45.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $174.86M | +79.6% | -8.9% |
| June 30, 2025 | $192.04M | +93.4% | +22.2% |
| March 31, 2025 | $157.13M | +11.4% | -14.4% |
| December 31, 2024 | $183.58M | +70.1% | +88.5% |
| September 30, 2024 | $97.38M | -17.4% | -1.9% |
| June 30, 2024 | $99.27M | -11.8% | -29.6% |
| March 31, 2024 | $141.08M | +75.0% | +30.7% |
| December 31, 2023 | $107.95M | -12.0% | -8.4% |
- Kiniksa Pharmaceuticals International, plc showed a decrease of -9.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Kiniksa Pharmaceuticals International, plc’s cash and equivalents has grown by 263.5% (from $45.55 million to $165.60 million).
- The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: